Articles

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

Department of Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, Sweden;Department of Pathology, Karolinska University Hospital, Stockholm, Sweden
Department of Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, Sweden
Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden
Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
King’s College Hospital, London, UK
King’s College Hospital, London, UK
Institute for Cell and Molecular Pathology, Medical University Hannover, Germany
Marien Hospital Düsseldorf, Germany
AZ ST-Jan Brugge AV, Brugge, Belgium
Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
Hospital Universitaria La Fe, Valencia, Spain
Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv, Israel
St James’s Institute of Oncology, Leeds, UK
Department of Laboratory Medicine and Pathobiology, Toronto General Hospital, Ontario, Canada
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Service d’Hématologie Séniors, Hôpital St Louis, Université Paris 7, France
Celgene Corporation, Summit, NJ, USA
Department of Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, Sweden
Vol. 99 No. 6 (2014): June, 2014 https://doi.org/10.3324/haematol.2013.098103